Palo Alto, United States
Aria Pharmaceuticals, founded in 2014, is a preclinical-stage pharmaceutical company based in the United States. The company specializes in the discovery and development of novel small molecule therapies, primarily targeting complex and hard-to-treat diseases. With a mission to accelerate drug discovery and increase success rates dramatically, Aria Pharmaceuticals harnesses the power of AI and Big Data to drive its innovative solutions in the Biotechnology and Health Care industries.
Noteworthy is their redefined drug discovery approach, which purportedly boosts success rates to be 30 times higher than traditional methods. This breakthrough has allowed Aria Pharmaceuticals to show potential in addressing over 1,000 diseases across various therapeutic areas.
The company secured a Series B investment on 09 July 2021, funded by notable investors including Future Planet Capital, Network. VC, and the Silicon Valley Syndicate Club. As an emerging leader in the pharmaceutical domain, Aria Pharmaceuticals presents a compelling opportunity for investors focused on trailblazing biotech innovation.
